MediWound Ltd   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Yevne Israel (2001)

Organization Overview

First Clinical Trial
2014
NCT02020746
First Marketed Drug
2022
anacaulase (NexoBrid)
First NDA Approval
2022
anacaulase (NexoBrid)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

MediWound Ltd | MediWound, Ltd. | MEDIWOUND, LTD